Fatty liver disease progresses through four main stages: simple fat buildup, inflammation, scarring (fibrosis), and cirrhosis. Not everyone moves through all four. Many people stay at the earliest stage for years or even a lifetime without progressing, while others advance more quickly depending on their metabolic health. The disease affects roughly 30% of the global population, making it one of the most common liver conditions in the world.
You may see two sets of names for this condition. Doctors recently renamed nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease, or MASLD. The inflammatory stage, previously called NASH, is now MASH. The new names reflect the fact that metabolic factors like obesity, insulin resistance, and high blood pressure drive the disease. The stages themselves haven’t changed.
Stage 1: Simple Fatty Liver (Steatosis)
The first stage begins when fat accumulates to more than 5% of your liver’s weight. A healthy liver contains some fat, but beyond that threshold, it qualifies as steatosis. The primary driver is increased fat production within the liver itself, a process called de novo lipogenesis, where the liver converts excess sugars and calories into fat and stores them in its own cells.
Most people at this stage have no symptoms at all. You might learn about it incidentally during an imaging scan for something else. The liver still functions normally, and there’s no inflammation or scarring. This is the most reversible stage. Losing weight, reducing sugar intake, or increasing physical activity can clear the excess fat entirely in many cases.
Stage 2: Inflammation (MASH)
In some people, the accumulated fat triggers an inflammatory response. Liver cells begin to swell and balloon, and immune cells move into the tissue. This stage, now called MASH (formerly NASH), is where actual liver damage starts. Pathologists identify it by looking for three features in a tissue sample: fat deposits, clusters of inflammatory cells, and visibly swollen (ballooned) liver cells. All three need to be present for a MASH diagnosis.
You still might not feel anything obvious at this stage. Some people experience fatigue or a dull ache in the upper right abdomen, but many remain symptom-free. The critical difference between stage 1 and stage 2 is that inflammation can trigger scarring. Not everyone with a fatty liver develops MASH, but those who do face a meaningfully higher risk of progressing to the next stages.
Stage 3: Fibrosis (Scarring)
When inflammation persists, the liver tries to heal itself by laying down scar tissue, just as skin forms a scar after a cut. This scar tissue, called fibrosis, gradually replaces healthy liver tissue. Fibrosis is graded on a scale from F0 to F4:
- F0: No fibrosis
- F1: Mild scarring around the small blood vessels in the liver (portal areas), with no bands of scar tissue connecting them
- F2: Moderate scarring, with a few bands (septa) of scar tissue forming between portal areas
- F3: Severe scarring with many bands of scar tissue throughout the liver, but the overall architecture of the organ is still intact
- F4: Cirrhosis, where scar tissue has fundamentally restructured the liver
The liver is remarkably resilient and can still perform its essential jobs through F1 and F2. By F3, however, liver function begins to decline, and the risk of progressing to cirrhosis rises significantly. Fibrosis at F2 or above is generally considered “significant” and prompts more aggressive monitoring and intervention.
Stage 4: Cirrhosis
Cirrhosis is the final stage, where so much scar tissue has replaced healthy liver tissue that the organ’s structure is permanently altered. The liver becomes stiff and nodular, and blood can no longer flow through it efficiently. The damage at this point is largely irreversible.
Doctors divide cirrhosis into two categories. Compensated cirrhosis means the liver is severely scarred but still managing to perform enough of its functions to keep you relatively stable. You may have few or no noticeable symptoms. Decompensated cirrhosis is when the liver can no longer keep up. Signs of decompensation include yellowing of the skin and eyes (jaundice), fluid buildup in the abdomen, bleeding in the digestive tract, and confusion or drowsiness caused by toxins the liver can no longer filter. Decompensated cirrhosis is a serious, life-threatening condition that may require evaluation for a liver transplant.
How Fast the Disease Progresses
Progression varies enormously from person to person, but research on biopsy-confirmed cases gives useful averages. In people with simple fatty liver (stage 1), fibrosis advances at roughly one stage every 14 years. In people who already have MASH with inflammation, it moves about twice as fast: one stage every 7 years. That means someone diagnosed with MASH and mild fibrosis (F1) could, on average, reach cirrhosis in about 21 years if nothing changes.
These are averages, not guarantees. Some people progress much faster. In documented cases, patients have jumped from moderate fibrosis to cirrhosis in as little as one year during periods of rapid metabolic decline. Others remain stable at the same stage for decades. The speed depends heavily on factors like weight changes, blood sugar control, alcohol use, and genetics.
How Each Stage Is Detected
Fatty liver disease is often silent through its first two or even three stages, which is why detection usually depends on testing rather than symptoms. Several tools can help identify where you fall on the spectrum.
A FibroScan is a specialized ultrasound that measures liver stiffness in kilopascals (kPa). Readings below about 8 kPa generally suggest no significant fibrosis. Values above 10.8 kPa point toward significant scarring, and readings above 17.8 kPa are consistent with cirrhosis. The same device can estimate fat content using a separate measurement.
Blood tests offer a simpler screening option. The FIB-4 index combines your age, platelet count, and two liver enzymes into a single score. A score below 1.3 puts you in the low-risk category for advanced fibrosis. A score of 3.25 or higher suggests possible advanced fibrosis and warrants further testing. Scores between those two values fall into an indeterminate zone where additional imaging or evaluation is typically recommended.
A liver biopsy remains the most precise method, especially for distinguishing simple steatosis from MASH, since inflammation and cell ballooning can only be definitively confirmed under a microscope. But because biopsies are invasive, they’re usually reserved for cases where non-invasive tests are inconclusive or where confirming the exact stage would change treatment decisions.
Which Stages Can Be Reversed
The first two stages are highly reversible. Simple steatosis can resolve completely with lifestyle changes, and MASH-related inflammation can subside when the underlying metabolic triggers improve. Even fibrosis, once considered permanent, can regress under the right conditions.
The key threshold appears to be weight loss of 10% or more of total body weight. In one study of patients with biopsy-confirmed MASH, 63% of those who lost at least 10% of their body weight showed fibrosis regression, compared to just 9% of those who lost less. On multivariate analysis, reaching that 10% threshold was the single strongest predictor of scar tissue improvement, with the odds of regression more than eight times higher. This held true even in patients with advanced fibrosis.
Cirrhosis is a different story. While compensated cirrhosis can be managed and its complications delayed, the structural damage is largely permanent. The goal at that stage shifts from reversal to preventing decompensation and screening for liver cancer, which cirrhosis significantly increases the risk for.
The practical takeaway across all stages: the earlier the intervention, the more reversible the damage. Because the disease is silent for so long, people with known risk factors like obesity, type 2 diabetes, or high triglycerides benefit most from proactive screening rather than waiting for symptoms to appear.